Delivery of microRNA-146a with polyethylenimine nanoparticles inhibits renal fibrosis in vivo

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 3475-3488

  Morishita, Yoshiyuki ^a   Imai, Toshimi ^a   Yoshizawa, Hiromichi ^a   Watanabe, Minami ^a   Ishibashi, Kenichi ^b   Muto, Shigeaki ^a   Nagata, Daisuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

End stage renal disease; Infammatory signaling pathway; Mir; Pro fibrotic signaling pathway

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 146A; NANOPARTICLE; POLYETHYLENEIMINE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; MICRORNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; FLUORESCENCE MICROSCOPY; GENE DELIVERY SYSTEM; GENE EXPRESSION; HISTOLOGY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY MASS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; URETER OBSTRUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG DELIVERY SYSTEM; FIBROSIS; KIDNEY FAILURE, CHRONIC; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FIBROSIS; KIDNEY FAILURE, CHRONIC; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; NANOPARTICLES; POLYETHYLENEIMINE;

EID: 84929448714     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S82587     Document Type: Article

References (43)

1. Becker GJ, Hewitson TD. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens. 2000;9(2):133–138.
2. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339(20):1448–1456.
3. Campanholle G, Ligresti G, Gharib SA, Duffeld JS. Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol Cell Physiol. 2013;304(7):C591–C603.
4. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000; 15(3–4):290–301.
5. Boor P, Floege J. Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol. 2011;38(7):441–450.
6. Meng XM, Huang XR, Xiao J, et al. Disruption of Smad4 impairs TGF-β/Smad3 and Smad7 transcriptional regulation during renal infammation and fibrosis in vivo and in vitro. Kidney Int. 2012;81(3): 266–279.
7. Krensky AM, Ahn YT. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol. 2007;3(3): 164–170.
8. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int. 2001;59(2):415–424.
9. Lange-Sperandio B, Trautmann A, Eickelberg O, et al. Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice. Am J Pathol. 2007;171(3):861–871.
10. Yang N, Wu LL, Nikolic-Paterson DJ, et al. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant. 1998;13(8):1967–1974.
11. Eardley KS, Kubal C, Zehnder D, et al. The role of capillary density, macrophage infltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int. 2008;74(4):495–504.
12. Wilson HM, Chettibi S, Jobin C, Walbaum D, Rees AJ, Kluth DC. Inhibition of macrophage nuclear factor-kappaB leads to a dominant anti-infammatory phenotype that attenuates glomerular infammation in vivo. Am J Pathol. 2005;167(1):27–37.
13. Anders HJ, Vielhauer V, Eis V, et al. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J. 2004;18(3):534–536.
14. Benfey PN. Molecular biology: microRNA is here to stay. Nature. 2003;425(6955):244–245.
15. Morizane R, Fujii S, Monkawa T, et al. miR-34c attenuates epithelial-mesenchymal transition and kidney fibrosis with ureteral obstruction. Sci Rep. 2014;4:4578.
16. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med. 2004;82(3):175–181.
17. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol. 2011;22(9):1668–1681.
18. Qin W, Chung AC, Huang XR, et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol. 2011;22(8):1462–1474.
19. Chung AC, Huang XR, Meng X, Lan HY. miR-192 mediates TGF-beta/ Smad3-driven renal fibrosis. J Am Soc Nephrol. 2010;21(8):1317–1325.
20. Wang B, Komers R, Carew R, et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol. 2012;23(2):252–265.
21. Oba S, Kumano S, Suzuki E, et al. miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS One. 2010;5(10):e13614.
22. Macconi D, Tomasoni S, Romagnani P, et al. MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol. 2012;23(9):1496–1505.
23. Li R, Chung AC, Dong Y, Yang W, Zhong X, Lan HY. The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-beta/Smad3-Azin1 pathway. Kidney Int. 2013;84(6):1129–1144.
24. Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 2012;23(3):458–469.
25. Selvamani SP, Mishra R, Singh SK. Chikungunya virus exploits miR-146a to regulate NF-kappaB pathway in human synovial fibroblasts. PLoS One. 2014;9(8):e103624.
26. Paik JH, Jang JY, Jeon YK, et al. MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res. 2011;17(14):4761–4771.
27. Comer BS, Camoretti-Mercado B, Kogut PC, Halayko AJ, Solway J, Gerthoffer WT. MicroRNA-146a and microRNA-146b expression and anti-infammatory function in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2014;307(9):L727–L734.
28. Yang K, He YS, Wang XQ, et al. MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and infammatory response via targeting toll-like receptor 4. FEBS Lett. 2011;585(6):854–860.
29. Ho BC, Yu IS, Lu LF, et al. Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I interferon. Nat Commun. 2014;5:3344.
30. Lv S, Sun B, Dai C, et al. The Downregulation of MicroRNA-146a Modulates TGF-β Signaling Pathways Activity in Glioblastoma. Mol Neurobiol. 2014. Epub October 19.
31. Huang Y, Liu Y, Li L, et al. Involvement of infammation-related miR-155 and miR-146a in diabetic nephropathy: implications for glomerular endothelial injury. BMC Nephrol. 2014;15:142.
32. Ji SM, Shin YB, Park SY, Lee HJ, Oh B. Decreases in Casz1 mRNA by an siRNA Complex Do not Alter Blood Pressure in Mice. Genomics Inform. 2012;10(1):40–43.
33. Hernandez-Vargas P, Lopez-Franco O, Sanjuan G, et al. Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells. J Am Soc Nephrol. 2005;16(6):1673–1683.
34. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009;75(11):1145–1152.
35. Morishita Y, Yoshizawa H, Watanabe M, et al. siRNAs targeted to Smad4 prevent renal fibrosis in vivo. Sci Rep. 2014;4:6424.
36. Lungwitz U, Breunig M, Blunk T, Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm. 2005;60(2):247–266.
37. Swami A, Kurupati RK, Pathak A, Singh Y, Kumar P, Gupta KC. A unique and highly efficient non-viral DNA/siRNA delivery system based on PEI-bisepoxide nanoparticles. Biochem Biophys Res Commun. 2007;362(4):835–841.
38. Lloyd CM, Minto AW, Dorf ME, et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med. 1997;185(7):1371–1380.
39. Humphreys BD, Lin SL, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010;176(1):85–97.
40. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112(12):1776–1784.
41. Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol. 2009;175(4): 1380–1388.
42. Broekema M, Harmsen MC, van Luyn MJ, et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol. 2007;18(1):165–175.
43. LeBleu VS, Taduri G, O’Connell J, et al. Origin and function of myo-fibroblasts in kidney fibrosis. Nat Med. 2013;19(8):1047–1053.